Asset profile
(Z)-endoxifen
Small molecule
Evidence outlook · lead readout
NCT03931928 · Breast Cancer, DCIS
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03931928: This was a randomized, participant-masked, placebo-controlled study of 356 patients, but its primary endpoint was a pharmacokinetic concentration threshold rather than a clinical or endoscopic outcome. Because no results or statistical comparison are posted, it cannot establish whether the primary endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.